Skip to main content

Table 1 Baseline demographic and clinical characteristics of participants

From: Dynamic changes in the gut microbiota composition during adalimumab therapy in patients with ulcerative colitis: implications for treatment response prediction and therapeutic targets

Characteristics

Patients with UC

(n = 131)

Age (years)

44.7 ± 14.9

Male sex, no (%)

46 (35.1)

Body weight (kg)

63.5 ± 12.6

BMI (kg/m2)a

22.6 ± 3.7

Age at diagnosis (years)

38.8 ± 14.5

Duration of disease (months)

52.1 ± 49.6

Mayo score

8.7 ± 1.4

Endoscopic subscore

2.5 ± 0.5

Disease location

 Proctitis

24 (18.3)

 Left-sided colitis

58 (44.3)

 Extensive colitis

49 (37.4)

Fecal calprotectin (mg/kg)

 Mean ± SDb

892.8 ± 628.1

C-reactive protein (mg/dL)

 Mean ± SD

4.6 ± 11.4

Albumin (g/dL)

 

 Mean ± SD

3.7 ± 0.6

Concomitant medication (overlapped), n (%)

 5- aminosalicylates

110 (84.0)

 Azathioprine/6-Mercaptopurine

61 (46.6)

 Systemic corticosteroid

41 (31.3)

 Prior anti-TNFc therapy, n (%)

33 (25.2)

  1 medication

32 (97.0)

  2 medications and above

1 (3.0)

  1. BMI: body mass index; SD: standard deviation; TNF: tumor necrosis factor